Athira Pharma, Inc. ATHA · Stock Open Athira Pharma, Inc. in new tab
Athira Pharma, Inc. Analysis (ATHA)
Is Athira Pharma, Inc. a good investment? Athira Pharma, Inc. (ATHA) is currently trading at 6.75 USD.
Earnings Schedule: Athira Pharma, Inc. is expected to release its next earnings report on May 7, 2026. The market consensus estimate for Forward EPS is -1.63.
Investor FAQ
Does Athira Pharma, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Athira Pharma, Inc.?
Athira Pharma, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be May 7, 2026. The company currently has a trailing EPS of -9.67.
Company Profile
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
| Split Date | Split Ratio to 1 |
|---|---|
| Sept. 18, 2025 | 1:10 |
Community Discussion